The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The FDA and CDC are investigating reports of serious adverse events, including deaths, in recipients of Ixchiq.

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events.

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

May 12 (UPI) --U.S. health officials are advising patients using the drug Ixchiq to hold off while authorities seek newer information on vaccine results in the global fight against chikungunya.

Valneva (VALN) stock is in focus as the U.S. recommends a pause in the company's chikungunya vaccine Ixchiq in adults 60+ ...